Immunotherapy, Lung Cancer, Non-Small Cell
Conditions
Brief summary
The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are: * Does pneumonectomy bring more benefits for pateints than lobectomy? * Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment and the study will analyze the data.
Detailed description
This observational study aims to comprehensively evaluate the effectiveness and long-term clinical outcomes of neoadjuvant treatment in patients with lung cancer. Central to this investigation are two key questions: ·Does pneumonectomy bring more benefits for pateints than lobectomy? * Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment, and through rigorous analysis of data, this study endeavors to provide nuanced insights into these fundamental queries, fostering advancements in clinical decision-making and patient management strategies.
Interventions
PROCEDUREPneumonectomy
Patients will receive pneumonectomy after neoadjuvant treatment
PROCEDURElobectomy
Patients will receive lobectomy after neoadjuvant immunotherapy.
RADIATIONradiotherapy
Patients will receive radiotherapy after neoadjuvant immunotherapy.
DRUGAnti-Tumor Drugs
Patients will receive anti-tumor drugs.
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 79 Years
Inclusion criteria
1. Aged between 18 and 79 years; 2. Received at least two cycles of neoadjuvant immunotherapy; 3. ECOG performance status score of 0; 4. Complete clinical information including imaging data available.
Exclusion criteria
1. Diagnosed with or suspected active autoimmune diseases; 2. Presence of EGFR/ALK sensitive mutations; 3. Pregnant or breastfeeding women; 4. Previous anti-tumor therapies including chemotherapy or radiotherapy; 5. History of organ transplantation or hematopoietic stem cell transplantation; 6. Interstitial pneumonia, pulmonary fibrosis, or severe emphysema; 7. Uncontrolled diabetes mellitus; 8. Uncontrolled hypertension.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event-free survival | Event-free survival was defined as the time from neoadjuvant treatment to metastasis or death by any cause in the absence of metastasis, up to approximately 10 years. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | From date of neoadjuvant treatment until date of death due to any cause, up to approximately 10 years. | — |
| Perioperative Complication rate | Within 6 months after neoadjuvant treatment. | Complications after the neoadjuvant treatment. |
Countries
China
Contacts
Primary ContactShugeng Gao, MD
Outcome results
None listed